journal article·2014-07-24Open access

The market trend analysis and prospects of scaffolds for stem cells

Seou Lee, Taehoon Kwon, Eun Kyung Chung, Joon Woo Lee

Biomaterials Research· Volume 18· Issue 1

Abstract

Abstract Background Scaffolds are one of the three most important elements constituting the basic concept of regenerative medicine, and are included in the core technology of regenerative medicine along with stem cells and tissue engineering. Stem cells are very important technology because they are directly responsible for the regenerative treatment of the disease and the damaged tissue, but with regards to the technology and the products that use stem cells exclusively, there is a technical limitation of limited survival rate and the engraftment rate of the transplanted cell, and rather than recovering the damaged tissue fundamentally, there is a limit that the concept is more of just another medicine treatment using cells. A scaffold is a natural or synthetic biocompatible material transplanted into a human body to be used as the exclusive treatment or as an assisted method of another treatment of a disease and for the recovery of damaged tissue. Therefore, according to the characteristics of the tissue to be applied, scaffolds must have the characteristics such as the excellent biocompatibility, biodegradability, minimum immunity and inflammation, proper mechanical strength and interaction between the material and the cells. Results The world stem cell market was approximately 2.715 billion dollars in 2010, and with a growth rate of 16.8% annually, a market of 6.877 billion dollars will be formed in 2016. From 2017, the expected annual growth rate is 10.6%, which would expand the market to 11.38 billion dollars by 2021. Meanwhile, the world scaffold element technology market was approximately 4.57 million dollars in 2013, and by increasing 13.4% annually, it is estimated to expand to 10.63 million dollars by 2020. The Korean scaffold element technology market was about 22 million dollars in 2013, and with a steady growth of approximately 13.4% every year, it is prospected to be about 52 million dollars by 2020. Conclusions In comparison to the medical material and medicine sales growth rate, the future scaffold element technology market is judged to be higher in growth possibility.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pluripotent Stem Cells Research · Diverse Topics in Contemporary Research · Diverse Approaches in Healthcare and Education Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Techbiz, Room No. 903, 26 Seochojoongang-Ro, Seocho-Gu, Seoul 137-918, Korea.

KISTI, 66 Heogi-ro, Dongdeamoon-gu, Seoul 130-741, Korea.

References (27)

Show source-provided references
1. Visiongain: Stem Cell Technologies World Market Outlook 2011–2021; 2010.
2. 10.1016/j.compscitech.2003.09.00110.1016/j.compscitech.2003.09.001 ↗
3. 10.1016/S0142-9612(03)00339-910.1016/S0142-9612(03)00339-9 ↗
4. 10.1016/j.copbio.2009.10.00310.1016/j.copbio.2009.10.003 ↗
5. 10.1016/j.ucl.2009.02.00910.1016/j.ucl.2009.02.009 ↗
6. 10.1016/j.fertnstert.2012.05.03810.1016/j.fertnstert.2012.05.038 ↗
7. 10.1126/scitranslmed.300489010.1126/scitranslmed.3004890 ↗
8. Rim N, Lee Y, Kim S, Shin H: Current status and prospect of biomaterials as tissue substitutes in regenerative medicine. Korean Ind Chem News 2010, 13(6):2–17.
9. 10.1016/S0090-4295(99)00179-X10.1016/S0090-4295(99)00179-X ↗
10. 10.1016/j.biomaterials.2007.05.02010.1016/j.biomaterials.2007.05.020 ↗
11. 10.1016/S0090-4295(97)00644-410.1016/S0090-4295(97)00644-4 ↗
12. 10.1007/s00345-008-0300-110.1007/s00345-008-0300-1 ↗
13. Korea Food and Drug Administration: A Study on Evaluation Criteria for Quality of Mesenchymal Stem Cell based Tissue Engineering Products: Searching for Molecular Biological Method; 2007.
14. Lee H, Khang G, Kim M, Rhee JM, Lee I, Min B: Scaffold for tissue engineering. Tissue Eng Regen Med 2006, 3(4):1738–2696.
15. LG Economic Research Institute: StemCell: Gap between Possibility and Reality; 2013.
16. Ehwa Womans University: Research on the Evaluation Method for Bioactive Medical Devices; 2009.
17. 10.7599/hmr.2012.32.3.12710.7599/hmr.2012.32.3.127 ↗
18. TriMark Publication: Regenerative Medicine Markets; 2013.
19. 10.1016/S0378-5173(01)00691-310.1016/S0378-5173(01)00691-3 ↗
20. 10.1016/S0142-9612(00)00423-310.1016/S0142-9612(00)00423-3 ↗
21. 10.1016/S0736-0266(02)00142-010.1016/S0736-0266(02)00142-0 ↗
22. Lee S, Yoo JJ, Atala A: Recent applications of polymeric biomaterials and stem cells in tissue engineering and regenerative medicine. Polymer 2014, 38(2):113–128.
23. Shinhan Investment Corp: Sector Report: Stem-Cell Theraphy Products; 2011.
24. 10 Growth Strategies for Stem Cell Industry. 2005 Korea Health Industry Development Institute.
25. Investment Strategies for Stem Cell Technology: Korean Ministry of Education Korean Ministry of Health and Welfare Korean Ministry of Knowledge Economy Korean Ministry of Agriculture Food and Rural Affairs; 2012.
26. HTStec: 3D Cell Culture Trends 2011; 2011.
27. Korea Health Industry Development Institute: Medical Resource Statistics Handbook; 2012.